Of particular interest, we identified a stop-gain variant, p.Q58*, in the APOL3 gene, with an AFR MAF of 0.211 and EUR MAF of <0.001, that is significantly associated with CKD risk independent of APOL1 G1/G2. This evidence concerns the gene APOL3 and chronic kidney disease.